Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis

• Үндсэн зохиолчид: Jagadeswara Rao Earla (Зохиогч), George J. Hutton (Зохиогч), J. Douglas Thornton (Зохиогч), Hua Chen (Зохиогч), Michael L. Johnson (Зохиогч), Rajender R. Aparasu (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Elsevier, 2021-06-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background: Fingolimod is the first approved oral disease-modifying agent (DMA) in 2010 to treat Multiple Sclerosis (MS). There is limited real-world evidence regarding the determinants associated with fingolimod use in the early years. Objective: The objective of this study was to examine the facto...